Interesting BSX Put And Call Options For April 17th

Boston Scientific (BSX) is trading at $96.52 and the article presents two options plays: selling a $95 put for a $2.00 bid (net cost basis if assigned $93.00), with an estimated 60% chance of expiring worthless and a 2.11% cash-return (8.09% annualized) YieldBoost; and selling a $100 covered call for a $2.50 bid, implying a 6.20% total return if called at April 17 and a 54% chance of expiring worthless, which would boost return by 2.59% (9.96% annualized). Implied volatilities are ~26% (put) and 27% (call) versus a 12‑month trailing volatility of 24%, and the piece frames these metrics as trade ideas and probability-tracked analytics for option-focused positioning.

Analysis

Market structure: Short-dated option sellers and buy-write investors directly benefit from selling BSX premium (Apr 17 example): cash‑secured $95 puts yield ~2.11% (8.1% annualized) and $100 covered calls boost yield ~2.59% (9.96% annualized). Med‑tech holders accept capped upside in exchange for yield; shareholders and long‑vol buyers lose optional upside and pay slightly elevated IVs (26–27% vs realized 24%). Cross‑asset impact is limited but a >10% BSX move would pressure healthcare peers, widen corporate credit spreads for similarly rated med‑techs and transiently lift equity implied vols.

Risk assessment: Tail risks include adverse FDA rulings, material device recalls or reimbursement cuts that could produce 20–40% equity shocks and trigger liquidity-driven IV spikes; biotech regulatory headlines are the highest‑probability catalyst within 90 days. Immediate (days) action centers on April 17 expiries (~3 months); short‑term (weeks) monitor IV vs realized; longer term (quarters) fundamentals — organic growth, M&A pipeline — drive valuation. Hidden dependencies: option P/L is sensitive to IV moving ±5–10pt and to corporate news; delta‑weighted position sizing is essential.

Trade implications: Prefer premium selling in BSX (net IV premium ≈2–3pts over realized) with risk‑limits: cash‑secured $95 puts or buy‑write $100 calls into Apr 17 for 1–2% portfolio exposures. For directional, consider pair trades vs larger med‑techs (e.g., long BSX / short MDT) to express relative outperformance; use put spreads or covered calls to define max loss and cap upside. Time entries on IV > realized and avoid naked short strangles without defined wings.

Contrarian angles: Consensus focuses on extracting short‑dated yield; misses that modest IV richness (≈+2–3 pts) could compress if no adverse news, making selling premia less attractive after rapid IV decay. Historical parallels (post‑recall recoveries) show med‑techs can mean‑revert over 6–12 months; a disciplined buy‑write + roll strategy can outperform outright stock buys if growth stalls. Unintended consequence: widespread put‑selling could create concentrated long exposure at similar strike levels, amplifying downside if a shock forces forced selling.

Key Decisions for Investors

• Sell-to-open BSX Apr 17 $95 cash‑secured put (collect ~$2) sizing to 1.0–1.5% of NAV (reserve $9,500 per contract); set automated buy‑back if BSX ≤ $88 or IV > 40% to limit tail loss, target realized yield 8%+ annualized.
• Implement a buy‑write: buy 100 BSX at market (~$96.50) and sell Apr 17 $100 call (collect ~$2.50) for 1–2% portfolio exposure; if stock > $100 before expiry, roll to Apr 17 $105 for net credit or let assignment to capture ~6.2% gross to call‑away.
• If preferring defined risk: establish a $95/$90 bull put spread Apr 17 (sell $95, buy $90) to cap downside (max loss ≈ $5‑credit) and pocket net premium; limit position to 0.5–1.0% NAV.
• Relative value: take a 0.5–1.0% pair trade long BSX / short MDT to express idiosyncratic BSX strength vs large cap med‑techs; rebalance if the spread narrows/widens by >5% absolute or on material FDA/earnings events within 60 days.